Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

Phase 3

Completed

Conditions: Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Bone Metastases in Subjects With Advanced Breast Cancer
Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma

Interventions: Drug: amg 162

First Posted Date: 2009-08-03

Last Posted Date: 2014-02-11

Lead Sponsor: Amgen

Target Recruit Count: 35

Registration Number: NCT00950911

Locations: 🇬🇧
Research Site, York, United Kingdom

A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism

Phase 2

Completed

Conditions: Hyperparathyroidism, Primary

Interventions: Drug: cinacalcet

First Posted Date: 2009-07-10

Last Posted Date: 2013-05-08

Lead Sponsor: Amgen

Target Recruit Count: 45

Registration Number: NCT00936988

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Phase 3

Completed

Conditions: Cataract
Low Bone Mineral Density
Osteopenia
Osteoporosis
Prostate Cancer
Cancer

Interventions: Biological: Denosumab
Biological: Placebo

First Posted Date: 2009-06-22

Last Posted Date: 2017-05-30

Lead Sponsor: Amgen

Target Recruit Count: 769

Registration Number: NCT00925600

Locations: 🇺🇦
Research Site, Zaporizhzhya, Ukraine

Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease

Phase 3

Completed

Conditions: Anemia
Chronic Kidney Disease

Interventions: Drug: darbepoetin alfa

First Posted Date: 2009-06-22

Last Posted Date: 2014-06-04

Lead Sponsor: Amgen

Target Recruit Count: 358

Registration Number: NCT00925587

Locations: 🇬🇧
Research Site, Wolverhampton, United Kingdom

A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women

Phase 1

Completed

Conditions: Osteopenia

Interventions: Drug: Placebo
Drug: AMG 167

First Posted Date: 2009-05-15

Last Posted Date: 2010-04-02

Lead Sponsor: Amgen

Target Recruit Count: 69

Registration Number: NCT00902356

A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab

Phase 2

Completed

Conditions: Low Bone Mineral Density
Osteoporosis
Postmenopausal Osteoporosis
Low Bone Mass

Interventions: Drug: Previous denosumab

First Posted Date: 2009-04-24

Last Posted Date: 2013-11-15

Lead Sponsor: Amgen

Target Recruit Count: 15

Registration Number: NCT00887965

Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis

Phase 1

Completed

Conditions: Cystinosis

Interventions: Drug: Cystagon®
Drug: RP103

First Posted Date: 2009-03-31

Last Posted Date: 2024-12-19

Lead Sponsor: Amgen

Target Recruit Count: 9

Registration Number: NCT00872729

Locations: 🇺🇸
University of California San Diego Medical Center, San Diego, California, United States

"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: MP-376 (Levofloxacin solution for Inhalation)

First Posted Date: 2009-02-10

Last Posted Date: 2024-12-04

Lead Sponsor: Amgen

Target Recruit Count: 27

Registration Number: NCT00840333

AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

Phase 1

Completed

Conditions: Cancer
Castrate-Resistant Prostate Cancer
Mestastatic Prostate Cancer
Prostate Cancer

Interventions: Drug: AMG 102
Drug: Placebo
Drug: Mitoxantrone
Drug: Prednisone

First Posted Date: 2008-10-10

Last Posted Date: 2014-03-10

Lead Sponsor: Amgen

Target Recruit Count: 162

Registration Number: NCT00770848

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Phase 1

Completed

Conditions: Cancer
Fallopian Tube Cancer
Oncology
Ovarian Cancer
Solid Tumors
Carcinoma
Tumors
Gynecological Malignancies
Metastases

First Posted Date: 2008-10-10

Last Posted Date: 2015-09-29

Lead Sponsor: Amgen

Target Recruit Count: 103

Registration Number: NCT00770536

Locations: 🇧🇪
Research Site, Wilrijk, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy